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ABSTRACT
Cutaneous T cell lymphoma (CTCL) is a heterogenous disease that can progress 
to leukemic involvement and is lethal in advanced stages. Toward a better 
understanding of the pathogenesis and identification of novel therapeutic targets 
in this malignancy of CD4+ T cells, we conducted an integrative high-resolution 
genomic analysis combining DNA and mRNA data, along with clinical 
information, from 24 CTCL patients with blood involvement. We further performed 
a consensus analysis, totaling 108 samples, that confirms and narrows key loci 
to produce one of the most comprehensive views of the CTCL genome to date. 
The most significant regions of alteration are amplifications on 8q and 17q and 
deletions on 17p and chromosome 10. We also discover specific focal 
amplifications containing KIT and EGFR, and adjacent to VEGFA, raising the 
possibility of targeted therapeutic interventions. Correlating with clinical 
phenotypes, we determine 17q25.1 amplification’s association with resistance to 
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4skin disease improvement and nominate candidate targets in this locus. Finally, 
we identify a gene expression signature of immunosuppression among patients 
who developed infections and secondary malignancies. Overall, we determine 
patterns in the CTCL genome with implications for pathogenesis and 
immunosuppression that may focus future therapeutic developments and the 
genetic classification of CTCL.
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6INTRODUCTION
Cutaneous T cell lymphoma (CTCL) is a clinically heterogeneous malignancy of 
CD4+ skin-homing T cells.  Mycosis fungoides and Sézary syndrome represent 
the most common forms in the spectrum of CTCL (1, 2).  First described nearly 
200 years ago by French physician Jean Louis Alibert, mycosis fungoides can 
present as erythematous flat patches, thin plaques or tumors.  These lesions 
tend to afflict areas of the skin infrequently exposed to sunlight, often have scale 
and can be numerous and of long-standing duration (3, 4).  Sézary syndrome, 
recognized in 1938 by Albert Sézary, is a more aggressive variant with diffuse 
skin involvement in addition to evidence of leukemic disease.  This malignant T 
cell disease, characterized by cerebriform nuclei known as Sézary cells, was 
classically identified by the triad of pruritic erythroderma affecting over 80% of 
body surface area, lymphadenopathy and other systemic manifestations and 
greater than 5% of Sézary cells (4).  The term cutaneous T cell lymphoma was 
coined in 1975 by Edelson and Lutzner and initially referred to these two most 
common forms of disease.  However, united by the common characteristic of a 
clonal expansion of T cells within at least the skin, many other entities are now 
also categorized under CTCL (2-4).  
Epidemiologically, cutaneous T cell lymphoma is a relatively uncommon disease 
with an overall age-adjusted incidence of CTCL from 1973 to 2002 of 6.4 cases 
per million in the US.  There has been an increasing incidence over the past few 
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7decades, however, this is likely a result of improved diagnosis.  Mycosis 
fungoides accounted for 72% of these cases whereas the leukemic form, Sézary 
syndrome accounted for 2.5%.  CTCL more commonly affects men than women 
with roughly a 2:1 frequency and is more common among African Americans than 
Caucasians.  Its incidence also increases greatly with age (3,4).
With significant heterogeneity in its presentation, the diagnosis of CTCL now 
relies upon integration of clinical, histopathological, immunopathological and 
molecular data.  Persistent and/or progressive patches or thin plaques in non-sun 
exposed areas with variations in size or shape and poikiloderma should raise 
clinical suspicion of CTCL.  Histopathlology, which may require serial biopsies to 
adequately identify disease, classically shows a superficial lymphoid infiltrate and 
atypical T cells with cerebriform nuclei  displaying epidermotropism without 
spongiosis.  Additionally, Pautrier microabscess, formations of malignant T cells 
and Langerhans cells aggregating in the epidermis, is a relatively specific, albeit 
not sensitive, finding for mycosis fungoides (3, 4).  In this malignancy of CD4+ T 
cells, immunologic markers can show an epidermal or dermal discordance of T 
cell antigens CD2+, CD3+, CD5+, and particularly loss of CD7+, and CD26+(4).  
Molecular criteria include evidence of clonal TCR gene rearrangements by PCR
(2, 3, 4).
Staging patients with CTCL at initial diagnosis can be helpful in guiding treatment 
and offers some prognostic information.  Tumor stage (T) is based on the size of 
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8patches and plaques, the presence of tumors >1 cm, or erythroderma, involving 
over 80% of body surface area.  The presence or absence of clinically abnormal 
lymph nodes or evidence of metastases determine nodal (N) and metastases (M) 
stage.  The degree of peripheral blood involvement (B) is based upon the 
percentage of circulating atypical cells present, and in more advanced stages 
additionally defined by an absolute malignant cell count >=1000 cells per 
microliter, a CD4/CD8 ratio >=10, aberrant expression of normal T cell markers, 
molecular evidence of clonality or chromosomal abnormality in a T cell clone (2, 
4).  T1 patients, with less than 10% body surface area involvement, often have a 
normal life expectancy whereas T4 erythrodermic patients have a median 
survival of 4-5 years and patients with visceral disease may only survive 1-2 
years.  Despite this TNMB staging, patients with mycosis fungoides do not 
uniformly progress through stages (4). 
Currently, the pathogenesis of CTCL is still unknown and investigations of 
infectious agents and occupational exposures have not yielded definitive 
causative etiologic factors (3).  Early stages of CTCL principally involve the skin, 
however the risk of peripheral blood involvement increases with advancing stage 
(5). The degree of clonal expansion of malignant cells within the peripheral blood 
is associated with a loss of T cell receptor diversity (6), T-regulatory activity (7), 
and diminished CD8 counts (8,9). CTCL patients are therefore at increased risk 
of complications of immune suppression including susceptibility to microbial 
infections and the development of secondary malignancies (10-13). While 
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9treatments such as photopheresis (14) and interferon-! (15) have demonstrated 
CTCL’s immunogenicity and responsiveness to immunotherapies, our 
understanding of the pathogenesis in this disease is still limited. Moreover, stage 
III and IV CTCL, especially in those with diminishing CD8 counts, is commonly 
lethal with survival not improved by conventional systemic therapies (8,9,14,15).
In recognition that cancer is fundamentally a genetic disease (16,17), knowledge 
of the critical mutations underlying tumor initiation and progression, along with a 
growing array of targeted therapeutics, offer tremendous potential in improving 
the diagnosis and treatment of cancer (18-20). Early cytogenetic studies in 
CTCL suggested that there might be commonalities in DNA copy number 
mutations (21,22) with 61% of samples showing chromosomal abnormalities 
(22).  Importantly some of these alterations, such as gain of 8q and loss of 6q 
and 13q, were associated with shorter survival (23).   These initial studies 
provided indicate that discernible patterns of mutations exist in CTCL and merit 
further investigation.
Additional characterizations have since bolstered this hypothesis with more 
potential candidate regions identified and previous regions narrowed (24-26).  
Vermeer et al. performed a copy number analysis that highlighted the 
significance of MYC, TP53, and genes in the IL-2 pathway as targets in the 
leukemic form of CTCL, Sézary Syndrome (24).  Laharanne et al. confirmed 8q 
gain, including MYC, as well as loss of 10q and 17p as alterations more common 
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in Sézary Syndrome (26).  JUNB has also been identified as a proto-oncogene 
and NAV3 as a potential tumor suppressor in this malignancy (4).  Each of these 
studies has advanced our understanding of the CTCL genome, however, past 
studies of CTCL traditionally focused on a single type of mutation. In the context 
of multiple levels of cellular dysregulation, this singular approach with restricted 
sample size, low-resolution data and limited clinical information has encumbered 
the discernment of the primary biological pathways in this malignancy.  More 
recently, in a matched copy number and expression analysis, Caprini et al. found 
genes in the NF-!B pathway to be perturbed and found better survival among 
patients with less than three copy number alterations(25).  Since then, microarray 
resolution has further increased and now, advances in microarray technologies, 
coupled with improved computational algorithms, offer the unique opportunity to 
characterize the CTCL genome to the sub-gene level and study various modes of 
mutations. 
The approach we now apply to CTCL has proven useful in identifying novel 
oncogenes and tumor suppressors in multiple other malignancies including some 
of the largest published studies in glioma, melanoma and lung adenocarcinoma 
(27-30).  A testament to the successes of our methodology has been the 
subsequent functional validation of many genes initially identified with this 
genomic algorithm in melanoma (29).  SETDB1 was first identified in a region of 
DNA copy number gain on 1q21.3 by our approach and this methyltransferase 
has since been found to be oncogenic in a melanoma zebrafish model (31).  
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ETV1 amplification on 7p and its consequent over-expression was also identified 
by this approach and found to cause melanoma tumor formation in mice (32). 
Finally, growing in vitro and mouse model evidence supports that KLF6, first 
identified with our genomic algorithm (29), is a tumor suppressor in melanoma 
(33).
Building upon this methodological framework applied in other malignancies, our 
characterization of the genomic landscape in CTCL at both the DNA and RNA 
level in the context of detailed clinical data pinpoints new targets and advances 
our understanding of the mechanisms underlying pathogenesis, and 
immunosuppression in this malignancy.
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STATEMENT OF PURPOSE AND SPECIFIC AIMS
The purpose of this study is to characterize the leukemic cutaneous T cell 
lymphoma (CTCL) genome and identify key oncogenes and tumor suppressors.  
By determining statistical outliers and patterns in DNA and RNA alterations in this 
disease and correlating them with clinical parameters, genes and biological 
pathways involved in pathogenesis can be identified and thereby focus the future 
development of biomarkers and targeted therapeutics in CTCL.
SPECIFIC AIMS
1. Generate high-resolution, patient-matched genomic data from primary 
leukemic cutaneous T cell lymphoma (CTCL) patients, including global DNA 
copy number gains/losses, and gene expression.
2. Determine statistically significant genetic alterations representing putative 
oncogenes and tumor suppressors through analysis of our data set and a 
meta-analysis of published data.
3. Integrate genomic data with gene expression data and correlate genetic 
alterations with clinical phenotypes to identify critical genes and biological 
pathways.
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MATERIALS AND METHODS 
Patient selection
CTCL patients were selected from the Yale Cutaneous Lymphoma Center clinic 
over a 3-month period in 2008.  Patients chosen had leukemic disease meriting 
treatment with photopheresis based on clinical assessment and evidence of 
blood involvement from FACS data.  Within this population, a reasonable 
diversity of clinical phenotypes and molecular markers on FACS analysis (such 
as CD4/CD8 ratios) ranging from predominantly early to some patients with late 
stage disease was also desired to characterize the spectrum of leukemic CTCL 
while identifying early genes involved in pathogenesis.  Exclusion and inclusion 
criteria are described below.  A final 24 patients were selected from which 
genomic data was generated. Written informed consent was obtained in 
accordance with the Declaration of Helsinki and approval was obtained from the 
Yale School of Medicine Human Investigation Committee 
(HIC protocols: 25269 and 23636). All of these patients were treated with 
extracorporeal photopheresis on a monthly basis for CTCL with blood 
involvement.  Some patients additionally received therapies such as bexarotene, 
methotrexate, interferon, or vorinostat. 
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Inclusion criteria: Exclusion criteria:
1. CTCL patients age !18 and "90. 1. Previous use of immunosuppressive 
regimens including multi-drug 
chemotherapy within 3 months.
2. At least T2 skin involvement and 
evidence of blood involvement taking into 
account CD3+, CD4+, CD8+, CD4+CD7+, 
CD4+CD7-, CD4+CD26+, CD4+CD26-, 
CD25+, CD4+CD25+, CD45RO, CD4/CD8 
ratios, presence of V# or V$ clones (34-36).
2. Known HIV or HTLV-1 positive patients.
3. Pregnant or nursing mothers.
Clinical data collection
Clinical information was gathered at the time of sample collection and one year 
later (Table 1).  A patient’s current status, skin disease, PET/CT results and 
lymph node status on physical exam were categorized into “Improved,” “Stable,” 
or “Worsened.” Current status was determined by physician global assessment. 
Skin disease was assessed taking into account changes over one year in body 
surface area and whether lesions were patches, plaques, tumors, or 
erythrodermic.
Isolation of malignant cell populations
In the final cycle of leukapheresis prior to 8-methoxypsoralen exposure, 10mL of 
lymphocyte-enriched blood was drawn from each patient. For normal controls, 50 
mL of whole blood were drawn from four volunteers chosen as most similar to the 
patient population based on age and sex. The blood sample was immediately 
layered on 4 mL of Isolymph (per 10 mL of blood, CTL Scientific Supply Corp.; 
Deer Park, NY) and processed as described by the manufacturer. Wash steps 
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used 10 mL of RPMI (Gibco; Carlsbad, CA) with 1% penicillin-streptomycin 
followed by 10 min centrifugation at 1200 RPM, 20°C. An extra incubation at 4°C 
in lysis buffer (Sigma; St. Louis, MO) prior to the final centrifugation was 
performed on samples with a visible amount of red blood cells.
Based on FACS data, expanded clonal populations "20% of the peripheral blood, 
believed to be enriched for malignant cells, were identified for isolation, focusing 
on CD4+CD7-, CD4+CD26-, and CD4+CD7 - CD26- populations. Otherwise, the 
CD4+ population was isolated. Negative selection using CD7 and/or CD26 mAb 
conjugated to biotin (eBiosciences; San Diego, CA; Miltenyi Biotech; Auburn, CA) 
and anti-biotin microbeads (Miltenyi Biotech) was performed first followed by 
positive selection using anti-CD4 Microbeads (Miltenyi Biotech). Following 
manufacturer’s instructions, populations were isolated using a Magnetic-bead 
Antibody Cell Sorting LS column and magnet (Miltenyi Biotech). Washes were 
done using filtered RPMI (Gibco) with 10% AB serum, 1% pencillin-streptomycin 
and 2mM EDTA. FACS was performed after isolation to confirm purity "70% 
(average 96%, median 99% CD4+).
Genomic data generation
From the isolated cells, RNA was extracted using Qiagen RNeasy kit and stored 
in RNAlater (Qiagen; Valencia, CA) and DNA was extracted using Puregene 
(Gentra; Valencia, CA) and stored in TE buffer.  After standard quality control 
measurements and quantitation, genomic data and total RNA were input into 
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their respective array assays. 500ng of genomic DNA was input in the PCR 
based Affymetrix Human SNP 6.0 assay so approximately 225ug of fragmented 
and labeled PCR product was hybridized to the human SNP 6.0 arrays 
(Affymetrix, Santa Clara, CA). Total RNA (300ng) was input in the Affymetrix 
Whole Transcript assay utilizing in vitro transcription and a second round of first 
strand cDNA synthesis to create the sense targeted single stranded DNA needed 
for hybridization. The sscDNA was fragmented, labeled and approximately 2.5ug 
was hybridized to the human Gene 1.0 ST arrays (Affymetrix) at the Keck 
Microarray Core facility according to manufacturer specifications.
Genomic Data Quality Controls
Affymetrix Expression Console software using the gene level RMA algorithm on 
all samples as a batch was used to assess quality metrics for hybridization and 
assay performance for the Affymetrix Human Gene 1.0 ST array. Perfect mean 
match were found to be in an acceptable range (298.2-402.7) compared to 
background values. Positive versus negative area under the ROC curve values 
to assess overall data quality were also acceptable (0.836-0.886).  All samples 
run on the Affymetrix human Genome wide SNP 6.0 arrays were found to have 
acceptable contrast quality control values (1.56-3.30) indicating sufficient 
contrast resolution quality for genotyping.
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Genomic Data Access
All genomic data will eventually be available in the GEO database (Accession 
number pending).  Temporarily, the raw genomic data may be downloaded at: 
http://ymd.med.yale.edu/ymd_prod/cgi-bin/gz_login.cgi Login information: 
Username: WGEO Passcode: ctcl. Please click on "SIMPLE MENU," then 
"Download Affy, Illumina, Nimblegen Files from Keck." From there, click on 
individual CEL files to save them to a local directory.
Copy number analysis
Genomic data was processed using algorithms written in MATLAB and packages 
in GenePattern [http://genepattern.broadinstitute.org/gp/pages/index.jsf] (37). 
Affymetrix .CEL files were converted to .SNP files by an adaption of SNP File 
Creator for SNP 6.0. GISTIC preprocessing and normalization was done as 
described previously using 5 nearest normals (29). Determination of significantly 
altered regions for copy-number used the genomic identification of significant 
targets in cancer (GISTIC) algorithm [Figure 1, Supplementary Table 1] (27,29).  
GISTIC parameters include: genome build: hg18, amplifications threshold: 0.1, 
deletions threshold: 0.1, join.segment.size: 8, qv.thresh: 0.25, remove.X: 1.  Copy 
number variants were removed as part of the GISTIC algorithm based on a 
database of genomic variants (file: variation.hg18.v8.txt, http://projects.tcag.ca/
variation/tableview.asp?table=DGV_Content_Summary.txt)
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Consensus analysis
Studies used in the consensus analysis focused on CTCL patients with blood 
involvement (Table 2). Lower resolution studies with sample number < 10 
included all available data. Higher resolution studies with > 10 samples only 
included regions identified by each study’s respective authors. Analyzing these 7 
studies, including our own data set, common regions were defined by at least 2 
studies and minimal common regions were defined by at least 1 study. Cancer 
related genes were annotated from genes identified in Beroukhim et al., 2010 
(28).
Cluster analysis
Significant regions of amplifications and deletions defined by GISTIC, were 
analyzed using hierarchical clustering [Pearson correlation, complete linkage] 
(Figure 2A). The matrix is comprised of regions of significant alteration by 
individual samples. In a particular cell, no amplification or deletion was assigned 
a value of 0, a low-level amplification or deletion (0.1< log2(copy number in 
region-1) <0.9) was assigned a value of 1, and high level amplification or deletion 
(0.9< log2(copy number in region-1)) was assigned a value of 2. 17q25.1 was 
identified through visual analysis of clusters and confirmed with Fisher exact test 
(Figure 2B). 
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Gene expression integration with DNA copy number
Gene expression was integrated with copy number through Comparative Marker 
Selection. Samples with or without an amplification in the region were compared 
to identify differentially expressed genes (Figure 2C). CLS and GCT files were 
created and input into the GenePattern module (parameters in Supplementary 
Material).  GSE17601 (25) was downloaded with GEOImporter and annotated 
using GeneCruiser. Comparative Marker Selection Parameters include: 
test.direction = 2, test.statistic = 0, number.of.permutations = 1000, complete = 
false, balanced = false, random.seed = 779948241, smooth.p.values = true.
Expression and pathway analysis
Differentially expressed genes between samples with the presence or absence of 
infections and secondary malignancies were identified with Class Neighbors 
analysis (default parameters) and Comparative Marker selection [parameters in 
Supplementary Material] (37). Overlapping genes were then input into 
Funcassociate 2.0 (38) (http://llama.med.harvard.edu/funcassociate/) to identify 
significant pathways (Figure 3).
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Materials and Methods Contributions
WML performed 1)patient selection, 2)clinical data collection, 3)isolation of 
malignant cell populations, 4)DNA and RNA isolation, 6)genomic data deposition, 
7)copy number analysis, 8)consensus analysis, 9)cluster analysis, 10)gene 
expression integration with DNA copy number, and 11)expression and pathway 
analysis.  KC performed 2)clinical data collection.  SR performed 4)DNA and 
RNA isolation.  AT and SU performed 5)genomic data generation and 6)genomic 
data deposition. GS and GG performed .CEL to .SNP file conversion as part of 7)
copy number analysis.
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RESULTS
Copy number analysis identifies regions containing putative oncogenes 
and tumor suppressors
Given that cancer progression is an evolutionary process, mutations that confer a 
survival advantage should be selected for and altered at a higher rate. Therefore 
identifying statistical outliers should determine regions of the genome with genes 
of potential biological significance. Our DNA based analysis seeks to determine 
these “driver” copy number mutations using an algorithm, termed GISTIC (27), 
which has identified known and novel oncogenes and tumor suppressors in 
multiple cancers (27-30). GISTIC takes into account both the frequency of a 
DNA gain or loss and the magnitude of this gain or loss at each probe. Then, 
comparing this calculated score to the background null hypothesis score, a 
significance value at each probe throughout the genome is determined. 
Significantly altered regions of the genome can then be further investigated for 
potential oncogenes and tumor suppressors.
The CTCL landscape for amplifications based on GISTIC analysis of our samples 
is shown in Figure 1A with significance per probe plotted across the genome. We 
identified 17 regions of amplifications in the CTCL genome seen in red (Figure 
1A, Supplementary Table 1A) and 40 regions of deletion in blue (Figure 1B, 
Supplementary Table 1B). The most significant amplifications involve large 
regions of gain on 8q and 17q, in addition to many focal amplifications. Overall, 
there were many more regions of deletion than amplification with the most 
Lin et al. Yale University School of Medicine Thesis
22
significant deletions on 17p and 10. These regions of chromosomal amplification 
and loss are shown in Supplementary Table 1. 
We also identified focal amplifications of 4q12 including KIT and 7p11.2 including 
EGFR. While these amplifications were only found in a subset of samples, 4 of 
23 (17%) and 3 of 23 (13%) respectively, half of those with KIT amplifications and 
all of those with EGFR amplifications had non-responsive or worsened skin 
disease after one year of treatment (Figure 4). The identification of these 
mutations in treatment non-responders is of potential clinical relevance given the 
availability of targeted therapeutics for these respective mutations. Moreover, 
VEGFA is another oncogene with an FDA-approved targeted therapy and is the 
closest well-validated gene to the focal amplification on 6p21.1 in 3 of 23 (13%) 
patients (Table 3). Thus, starting from the whole genome, the GISTIC algorithm 
begins to narrow and prioritize the list of candidate genes.
Consensus analysis of the leukemic CTCL genome
The clinical heterogeneity and relative rarity of CTCL combined with the difficulty 
in culturing and isolating malignant cells have hindered the genomic 
characterization of CTCL. To address some of these concerns, we performed a 
meta-analysis of published data, integrating regions of amplification and deletion 
from 108 samples comprising 7 studies, including our own, to create a 
consensus view of the CTCL genome (Table 2). In total, we determined 21 
regions of amplification and 42 regions of deletion. Notably, all of our samples 
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had significant copy number alterations and many patterns in the consensus 
analysis mirrored our GISTIC analysis (Supplementary Table 1), corroborating 
our data set. A majority of minimal common regions were narrowed and defined 
by our study (38 of 63 regions) and there were no instances where a region was 
found in all of the studies except ours. Annotating these regions, we identified 
known oncogenes and tumor suppressors in addition to new candidates not 
previously reported. The most significant gain lies in a broad region on 8q, 
including MYC. This finding supports results from Vermeer et al. and Laharanne 
et al. suggesting MYC’s primary role in oncogenesis (24, 26). The second most 
significant region of gain encompasses a large region on 17q that has yet to be 
fully studied in CTCL. STAT3 has previously been suggested as a candidate of 
gain at this locus (24), however in our analysis, STAT3 is in a significant region 
but not at the peak, implying that there may be other gene targets of the 
amplification and drivers of oncogenesis on 17q. While our analysis identifies 
genes involved in many cancers, CTCL-specific oncogenes were also 
considered. A focal amplification of 10p13 including GATA3, a transcription factor 
believed to promote T-helper 2 (TH2) cytokine skewing (39, 40), was also 
identified. GATA3’s importance in CTCL was previously proposed based on a 
supervised gene expression analysis (41). Its amplification in malignant cells may 
thus represent one mechanism of its activation and consequent CTCL mediated 
immune suppression via TH2 production. Deletions were most commonly found 
on chromosome 17p with TP53 nearby, chromosome 10 including PTEN, 13q 
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including RB1, and 9p21.3 including CDKN2A, reaffirming previous findings 
(24-26).
17q amplification associated with stable/progressive skin disease
Ultimately, one of the goals of cancer genomics is tying patient genotype to 
clinical phenotype to better understand pathogenesis and identify opportunities to 
therapeutically intervene. After defining the most significant copy number 
alterations in CTCL, we used unsupervised pattern recognition algorithms to 
determine whether any clinical phenotypes were linked to copy number 
alterations (Figure 2A). Using hierarchical clustering, we found that 17q25.1 
amplification was associated with patients who did not appear to improve and 
had stable/worsened skin disease after one year of treatment (Fisher exact test, 
p-value 0.026; Figure 2B). Seeking to identify candidate targets of amplification 
at this locus, we integrated gene expression data with our copy number analysis. 
Comparing samples with and without 17q25.1 gain, we identified genes that were 
both amplified and differentially over-expressed. This analysis was additionally 
done in an independent matched data set of CTCL samples with blood 
involvement by Caprini et al. (25). Two genes from our consensus analysis were 
identified: RPS6KB1 from analysis of the Caprini et al. data set and GRB2 from 
our data set. RPS6KB1 is involved in the PI3K/mTOR pathways and its 
amplification and over-expression is believed to affect prognosis in breast cancer 
(42). GRB2 is involved in MAPK signaling and therapeutic targets are already 
under development(43). Finally, overlapping genes in common include: 
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PRKAR1A and USP32 (Figure 2C). In particular, PRKAR1A regulates cAMP 
levels and has been found to induce three-to-four fold increased expression of 
IL-2 when it is over-expressed (44). Moreover, we found that IL-2 receptor beta 
expression, the subunit which binds IL-2 and has been specifically linked to 
proto-oncogene induction (45), was concordantly highest in patients with 
PRKAR1A amplifications in comparison with those without amplifications. Thus, a 
theoretical oncogenic model would be that PRKAR1A amplification is one 
mechanism of IL-2 pathway activation. This then leads to further malignant T cell 
proliferation through up-regulation of JAK/STAT, PI3K/AKT, and MAP kinase 
pathways (44-46), ultimately resulting in a clinically observed treatment-resistant 
skin disease.
Correlating molecular alterations with clinical phenotypes of 
immunosuppression
Patients with CTCL often suffer from the immunosuppressive effects of the 
disease, however the mechanism by which this occurs is not well understood 
(7-10). A subset of the patients we studied developed new infections and 
secondary malignancies after their diagnosis and treatment of CTCL (Table 1). 
Comparing the gene expression of three patients with B-cell lymphoma, spinal 
abscess and herpes zoster to patients who did not develop any infections or 
secondary malignancies determined a gene expression signature shown in 
Figure 3. The genes in this expression signature range from chemokines to 
antibody receptors to glycoproteins to serine-threonine kinases to transcription 
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factors.  Pathway analysis of these genes found to be relatively down-regulated 
in patients with infections and secondary malignancies revealed many key 
processes of the normal immune system including leukocyte chemotaxis, 
migration, chemokines and cytokine production, and cellular migration and 
movement. Overall, this gene expression signature suggests a degree of 
immunosuppression in patients who developed infections and secondary 
malignancies.
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DISCUSSION
We are currently in the early stages of CTCL genomics still defining the genetic 
landscape, and CTCL continues to offer unique opportunities to study T cell 
biology and cancer. Advances in genomic technology along with improved 
modeling and an increasing number of genomic studies are steadily expanding 
our knowledge of the mutations underlying malignant T cell transformation of 
CTCL.  Our high-resolution analysis and meta-analysis of patients with leukemic 
disease discerns some of the common DNA copy number alterations 
characteristic of CTCL, and we will continue to learn more as we study the 
mutations of patients with patch, plaque, tumor, erythrodermic and blood 
involvement and those ranging from the earliest to the most advanced stages of 
disease.
Despite their promise, genomic studies in CTCL must navigate many challenges.  
Foremost are limitations presented by sample size and data quality, which are 
affected by both the purity and yield of malignant cell isolation.  These hurdles, 
largely due to the low incidence and heterogeneity of disease and technical 
options available, continue to restrain the potential contribution of genomics to 
our understanding of CTCL biology.  Our desire to understand key genes in 
pathogenesis led us to incorporate a spectrum of CTCL patients, but primarily 
focusing on those with earlier stages of disease.  Characterizing early leukemic 
disease makes these concerns about malignant cell isolation particularly critical 
to consider.  Ultimately, we chose to use immunophenotypic markers CD7 and 
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CD27 to maximize the enrichment of the malignant cells in the population we 
isolated.  The loss of CD7 expression has often been correlated with expansion 
of clonal T-cells in CTCL, and taken together with observations from Rappl and 
colleagues that a CD4+CD7- phenotype was found in all clonal TCR VBeta cells 
from seven CTCL patients suggests that the dominant clone can, in at least some 
cases, arise from this subset (36).  While, this CD4+CD7- phenotype can also be 
found in reactive T-cell populations, it is nevertheless the most common major T-
cell antigen lost, with 46% to 76% of leukemic CTCL patients showing decreased 
CD7 expression (47).  Similarly, CD26 has also been used as another marker for 
leukemic CTCL.  With its use first described by Bernengo et al. (48), CD26 loss 
has also been confirmed in clonal T-cell populations and has been estimated to 
occur in 59.3% of Sézary syndrome patients (47).  Notably, it has been found to 
significantly correlate with the percentage of Sézary cells within the lymphoid 
population (48), and Bernengo et al. also observed significantly expanded 
CD4+CD26- populations in patients with CD4/CD8 ratios less than 10 (48). 
Overall, neither of these markers are ideal as there exist normal cells expressing 
these immunophenotypes; however, in the setting where there was a CD7- or 
CD26- population expanded outside of normal ranges, we utilized these markers 
in hopes to more specifically select and enrich our isolation for the dominant 
malignant clone.
The potential ramifications of reduced malignant cell purity affects all leukemic 
CTCL genomic studies and the resulting data must be viewed in light of isolation 
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methodology limitations and the patient population.  Gene expression values can 
be biased as a direct result of cell population contaminants.  DNA copy number 
changes are theoretically more robust, but there can be attenuation of absolute 
signal from normal cell admixture.  Strikingly, all of our samples had copy number 
alterations, however had they not, due to isolation of the incorrect population of 
cells or selection of a patient with undetectable malignancy, one safeguard in our 
copy number algorithm is to correct for this theoretical case and to remove 
samples without any significant copy number changes from inclusion in further 
analysis.  Additional concerns about the data quality are also partially alleviated 
through meta-analysis which enabled not only increased sample size but also 
allowed us to place our study in the proper context.  Our consensus analysis 
included 6 other genomic studies which were selected focusing on Sézary 
syndrome patients, often with more advanced leukemic disease.  The results of 
this analysis and the similarities of alterations on a genome-wide level between 
our data and other data sets corroborates our own analysis.  Indeed, it appears 
our samples captured a large proportion of the genomic diversity in leukemic 
CTCL with some patterns characteristic of malignancy observed even in our 
patients with early stages of blood involvement.  Also, including data and analysis  
from 108 patients enabled us to determine recurrent commonalities in DNA copy 
number alterations resulting in one of the more comprehensive descriptions of 
the leukemic CTCL genome.  At the same time, we recognize that this view 
reflects an evolving picture which we hope will be built upon and refined by future 
studies to further our understanding of the genomic landscape in CTCL. 
Lin et al. Yale University School of Medicine Thesis
30
While the genomic landscapes are similar from a global view between our 
patients with early leukemic disease and other studies of patients with more 
advanced disease, we also make direct comparisons at individual loci.  By 
generating our own high resolution data set and then using an algorithm that 
identifies driver genetic mutations, we narrow and verify significant regions of 
gain and loss in leukemic CTCL. Our analysis confirms findings from previous 
studies such as the significance of 8q amplification including MYC, chromosome 
10 loss including PTEN and FAS, 9p21.3 deletion including CDKN2A, 13q 
deletion including RB1, and 17p loss including TP53.  In addition, we begin to 
narrow known regions on 17q, and identify new loci and genes of interest, some 
with available targeted therapeutics. 
Directly addressing the potential clinical importance of our work, we notably 
discover copy number amplifications within or adjacent to KIT, EGFR, and 
VEGFA. Cancer is increasingly classified and additionally defined by key 
mutations. In part driven by our expanding arsenal of targeted therapeutics and 
the knowledge that copy number amplifications can predict sensitivity to targeted 
therapeutics, leading to increased survival (49), the discovery of these 
amplifications obligates further study as to whether a subset of CTCL patients 
may benefit from targeted therapies such as imatinib, erlotinib, and bevacizumab, 
respectively. While in vitro validation and testing is certainly warranted, 
this question’s importance is only further emphasized knowing that the skin 
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disease of a subset of the patients with apparent KIT and EGFR amplifications 
are not improving with currently available treatments.
In addition to the potential therapeutic ramifications of these findings, these focal 
amplifications also suggest that these genes and their products may play an 
intriguing role in mediating pathology. CTCL cells display a survival advantage 
within the skin, and the ligands for KIT (stem cell factor) and EGFR (epidermal 
growth factor) are both readily produced in the skin, raising the possibility that 
these factors stimulate CTCL within the cutaneous environment. In addition, 
VEGFA was shown to be spontaneously produced by CTCL cells, and is 
implicated in stage-dependent angiogenesis observed within cutaneous lesions 
(50). While further in vitro and in vivo studies are necessary, what role these 
genes play in the malignant milieu and whether patients who harbor these 
mutations may benefit from targeted therapeutics represent exciting prospects in 
the further understanding and treatment of CTCL.
Clinical data is of great benefit in modeling mutations in cancer and we 
demonstrate two instances where correlating genotype to clinical phenotype 
delineates important biology.  Our cluster analysis of significant copy number 
alterations in correlation with skin disease severity led to identifying 17q25.1 
amplification as associated with stable/progressive skin disease one year after 
treatment.  While it could be argued that treatment was not optimized in these 
patients and it is difficult to account for any potential impact they may have, the 
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fact that 17q25.1 was also the second most significant region of amplification and 
that a total of ~44% samples from our consensus analysis included 17q25 gain 
suggests that there are genes at or near this locus driving oncogenesis.  Utilizing 
orthogonal genomic expression data focusing on samples that are amplified and 
differentially over-expressed in 2 data sets, PRKAR1A was nominated from our 
list of candidates.  Given the importance of the IL-2 pathway in CTCL and the 
availability of Denileukin difitox (45), PRKARK1A represents an interesting target 
meriting further study. It is important to note, however, that broad gain of 17q 
suggests multiple oncogenic targets and therefore PRKAR1A is likely not the sole 
focus of amplification. Indeed, GRB2 and RPS6KB1 represent other potential 
candidates. Thus, while PRKAR1A's potential role in activating the IL-2 pathway 
is conceivable, more importantly, our analysis draws attention to the 17q locus 
and provides a framework with which to prioritize future functional work. 
Recognizing the immunosuppressive effects of CTCL and the complications that 
these patients consequently suffer, we were also interested in studying molecular 
markers of patients who developed infections and secondary malignancies 
versus those who did not.  While sample number is severely limited, the 
statistically significant results of our pathway analysis essentially reflects what we 
see clinically.  Further study of this signature may provide new insight into 
mechanisms of immunosuppression.  Moreover, if biomarkers for this phenotype 
can be identified, this would enable identification of patients at risk for 
immunosuppression and facilitate stratification for increased screening or 
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prophylactic treatment.
The genomic characterization of CTCL presents both new opportunities and 
challenges. As our view of the genomic landscape focuses, there will be an 
increasing shift toward modeling the interactions between oncogenes, tumor 
suppressors and their mediators and ultimately understanding the malignant T 
cell in the context of its immunologic environment.  While there is considerable 
complexity to these systems, insights gained from these models will likely 
facilitate the delineation of clinically relevant molecular subsets in CTCL. 
Ultimately, the foremost indicator of clinical relevance will be the translation of 
these discoveries to the development of biomarkers and targeted therapeutics.  
The identification of novel oncogenes in CTCL may spur new indications of 
approved therapies in addition to identifying rational drug targets.  Looking 
toward pre-clinical testing, functional validation of genomic hypotheses will 
require robust, genetically characterized in vitro and in vivo models. Continued 
genomic discoveries correlating genotypes to clinical phenotypes will enable 
additional avenues and insights into the interface of cancer biology and 
immunology in this malignancy.
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FIGURE AND TABLE LEGENDS
Figure 1. Significant DNA copy number alterations in leukemic CTCL 
Statistically significant (a) amplifications and (b) deletions pinpointed by GISTIC 
aggregate analysis of 23 CTCL patient samples. Chromosomal location is across 
the bottom with labeled cytobands corresponding to the center of the region and 
cancer related genes from Beroukhim et al. or known CTCL genes labeled above 
the region. * denotes a gene adjacent to the peak region. Significance is reported 
as false discovery rate corrected q-values.
Figure 2 17q25.1 amplification associated with stable/progressive skin 
disease (a) Unsupervised analysis of significant copy number mutations in 
CTCL as defined by GISTIC analysis was done with hierarchical clustering. Each 
patient’s skin disease severity after one year of treatment is annotated next the 
the sample number. (b) Fisher exact test shows an association between 17q25.1 
amplification and stable/worsened skin disease after one year of treatment. (c) 
Using Comparative Marker Selection, differential expression analysis of samples 
with 17q25.1 amplification versus no amplification reveals candidate targets that 
are amplified and differentially over-expressed in the Caprini et al. (shown in red), 
our (shown in blue) data sets and the overlap (shown in purple).
Figure 3 Gene signature in CTCL patients with infections and secondary 
malignancies Gene expression of patients with and without infections and 
secondary malignancies was compared using two differential gene expression 
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algorithms, ClassNeighbors analysis and Comparative Marker Selection. 
Pathway analysis with Funcassociate 2.0 was then performed with the genes in 
common from the two independent differential expression analyses.
Figure 4 Potential CTCL targets with available targeted therapies GISTIC 
analysis identifies focal amplifications of 4q12, 7p11.2, 6p21.1 including or 
adjacent to candidate genes KIT, EGFR, and VEGFA. (a) The relative frequency 
of these amplifications in our data set is shown in addition to skin disease 
response to treatment one year later.  A panel of selected therapies commercially 
available targeting the specific candidate genes is also included.  (b) Heatmap 
views of DNA copy number alterations for all the samples at the three loci are 
shown.  Red indicates amplification, white indicates no alteration and blue 
indicates deletion with the degree of color intensity indicating the magnitude of 
the alteration.  The samples that determined the peak from the GISTIC analysis 
are marked with an *.  The darker * indicates stable/worse skin disease whereas 
the lighter * indicates improved skin disease.  Genes are indicated on the bottom 
with their relative size.  
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Table 1 CTCL Patient Characteristics
Clinical data was collected from the 24 CTCL patients with blood involvement 
and various clinical parameters are shown to help describe our patient 
population.
Table 2 Consensus Analysis of CTCL amplifications and deletions
Analyzing 7 CTCL genomic studies, common regions of amplification (shown in 
red) and deletion (shown in blue) were defined by at least 2 studies and the 
minimal common region was determined by at least 1 study. The first column 
indicates the chromosome number. The second column indicates the number of 
studies including the minimal common region. Cancer related genes from 
Beroukhim et al., 2010 are shown in the final column.
Supplementary Table 1 Significant amplifications and deletions in CTCL
Corresponding with Figure 1, a rank list of significant copy number alterations 
and further details of each peak region including genes within the region are 
shown from the GISTIC analysis.
Lin et al. Yale University School of Medicine Thesis
Figure 1: Significant Amplifications and Deletions in CTCL
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Figure 2: 17q25.1 amplification associated with stable/progressive skin disease
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Figure 3: Gene signature in patients with infections and secondary malignancies
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Table 1: CTCL Patient Characteristics
Patient
Sample Gender Age
Current 
Status Skin Score PET/CT results
Lymph Node 
status on 
physical exam
Complete 
Remission
Infections and 
secondary 
malignancies
Valpha/
Vbeta
CD4/CD8 
ratio Type
Gene 
Expression 
Data
SNP 
data
1 Male 85 Stable Improved No Data Stable No
Past history of 
esophageal and 
prostate cancer 
No 1.7 CD4+ - Yes
2 Female 86 Stable Improved Stable Worsened No Breast Cancer No 1.6 CD4+CD7-CD26- - Yes
3 Male 67 Stable Improved Improved Stable No B-cell lymphoma Yes 2.9 CD4+ Yes Yes
4 Female 50 Stable Improved No Lymphadenopathy Stable No No Data No 38 CD4+CD7- Yes Yes
5 Male 66 Deceased Stable No Data Improved No No Data No 99 CD4+CD7-CD26- Yes Yes
6 Male 52 Improved Improved Worsened No Data Yes Past history of SCCs No 2.3 CD4+ - Yes
7 Female 76 Improved Improved No Lymphadenopathy No Data Yes Past history of Uterine cancer. SCC No 0.79 CD4+ Yes Yes
8 Female 83 Improved Improved No Data No Data Yes Osteomyelitis Yes 0.28 CD4+ - Yes
9 Male 54 Stable Stable No Data Stable No Spinal abscess No 1.2 CD4+ Yes -
10 Female 87 Worsened Worsened Improved Worsened No VZV Yes 19.7 CD4+CD26- Yes Yes
11 Female 73 Worsened Stable No Data Stable No No Post-CTCL disease No 3.5 CD4+CD7-CD26- Yes Yes
12 Male 63 Improved Improved No Lymphadenopathy Stable Yes No Post-CTCL disease No 2.8 CD4+CD7-CD26- Yes Yes
13 Male 32 Improved Improved Worsened Stable No No Post-CTCL disease No 1.6 CD4+ - Yes
14 Male 77 Stable Worsened Worsened Stable No No Post-CTCL disease No 18.5 CD4+CD26- - Yes
15 Female 57 Improved Improved No Data Stable Yes No Post-CTCL disease Yes 1.4 CD4+ - Yes
16 Male 84 Worsened Worsened No Data Worsened No No Post-CTCL disease Yes 4.9 CD4+CD7-CD26- - Yes
17 Female 81 Improved Improved No Data Improved Yes No Data No 3.3 CD4+ Yes Yes
18 Female 89 Deceased Improved No Data Stable No No Data Yes 3.6 CD4+CD26- Yes Yes
19 Male 54 Stable Improved Improved Improved No Past history of SCC, possible VZV No 3.1 CD4+ Yes Yes
20 Male 66 Stable Improved No Data Stable No No Post-CTCL disease Yes 3.4 CD4+CD7-CD26- Yes Yes
21 Male 76 Deceased Stable Improved Improved No Past history of VZV No 7.5 CD4+CD7-CD26- - Yes
22 Male 64 Deceased Improved Stable Improved No B-cell lymphoma Yes 7.6 CD4+ - Yes
24 Male 46 Improved Improved Improved Improved Yes Vitiligo No 3.1 CD4+ - Yes
25 Female 38 No Data Stable Improved Stable No No Data No 1.2 CD4+ - Yes
Chr Minim al Com monReg ion
Num ber
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stu dies
Can cer G enes Chr Minim al Com monReg ion
Num ber
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stu dies
Can cer G enes Chr Minim al Com monReg ion
Num ber
of
stu dies
Can cer G enes
1p13-1p31(+) 2 9p21.3(-)* 3 CD KN 2A 17p12(-)* 7 MAP2K4, Z NF 18
1p22( -) 2 9q21.2(-)* 4 17p13.3(-)* 7
1p36.11(-)* 3 SFN
9
9q34( -) 2 17p11.2(+) 2 MAP K7
1p36.13(+)* 2 10p11.22(-)* 5 17q21.31(+) 5
1
1q32-1q43(-)* 2 RYR2, FH,
ZNF678
10p11.23(-)* 5 17q23(+)* 6 RP S6KB 1
2p22-2p24(-) 2 10p15.1(-)* 5
17
17q25.1(+)* 5 GRB2,
ITGB42
2q37.1(-)* 2 10q21.1(-)* 5 18(+) 2
3p14-3p21(+) 2 10p13(+)* 5
18
18p11.1-18p11.3( -) 2
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10
10q26(-) 5 MGMT, SYC E1 21 No cons ensus region
5q14.3(-) 2 11 11q22.3(-)* 2 22 22q12-22q13(-) 3 TUBGCP6
5q21-5q23(-) 2 APC 12p13.2(-)* 2 ETV65
5q33.1(-)* 2 12q15(-)* 2
6 6p21.1(-)* 2 12q21.1(-)* 2
7p11 .2(+)* 3 EGFR
12
12q25(-) 2
7p21.1(+) 3 13q14(-) 4 RB17
7q35(+)* 3 13q21.1(-)* 4
8p11 .21(-)* 3 13q22pter(-) 4
8p23.2(-)* 3 CSMD1
13
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8p23.3(+) 4 15 No cons ensus region
8q23.3(+)* 7 16q24(-) 2 C16o rf3
8q24.1-q24.2(+)* 6 NOV 16p11.2(-) 2
8
8q24.2-q24.3(+)* 6 MYC 16p13.12(-)* 2
16
16p12.3(-)* 2
Minimal Common Regions
Gain: 21  Loss: 42
Red region i ndic ates copy gai n
Blue reg ion indicates copy loss
(Co m mon region de fined from at least 2 studies)
Minim al c om mon region de fined by at least 1 study
38 Regions italicized with * were  found in L in et al. ana lysis
Num ber of studies indicates the num ber of studies t ha t inc luded
the minimal  common region
Can cer G enes represent s ignific an tly am plified or dele ted genes
in c anc er from Bero ukhim et al. (PMID: 20164920,
Su pplementary Table 2: GISTIC analysis of 3 ,131 canc er
sp ecimens, 26 tumor types).
Mao et al. Mao et al. Fischer et al. Vermeer et al. Caprini et al. Laharanne et al. Lin et al.
Year 2002 2003 2004 2008 2009 2010 Unpublished
Samples 10 9 4 20 26 16 23
Method CGH CGH CGH CGH SNP CGH SNP
Resolution Low Low Low 3.5K 10K 105K 1800K
Region
Defined Tab le 1 Tab le 1 Tab le 1 By Authors By Authors By Authors By Authors
Table 2: Consensus analysis of the leukemic CTCL genome
Supplementary Table 1A: Significant regions of DNA copy number amplification in CTCL
Rank Cytoband Q-Value Numberof Samples Region Genes in region
Genes of interest 
related to region
1 8q23.3 3.44E-08 14 chr8:112360671-115742135 1 gene: CSMD3 MYC*
2 17q25.1 1.84E-05 8 chr17:40531449-75546555 371 genes NGFR, PHB, RPS6KB1, 
BPTF, GRB2, ITGB4, MIR21, 
PRKAR1A, USP32
3 1p36.13 0.000945 5 chr1:19256834-19274554 1 gene: UBR4 -
4 3p11.1 0.00429 8 chr3:90106010-96880237 5 genes: PROS1, NSUN3, ARL13B, DHFRL1, STX19 POU1F1*
5 6p21.1 0.00596 2 chr6:43979350-43993064 1 gene: C6orf223 VEGFA*
6 8p23.3 0.00950 8 chr8:577114-1646102 2 genes: DLGAP2, ERICH1 -
7 10p13 0.0128 3 chr10:4275516-17978213 75 genes: PFKFB3, PTPLA, ST8SIA6, STAM, OLAH, AKR1C3, CDC123, GATA3, SEC61A2, NUDT5, ACBD7, PRKCQ, VIM, 
SFMBT2, IL2RA, OPTN, FBXO18, USP6NL, RBM17, HSPA14, TAF3, AKR1CL1, tAKR, PHYH, TRDMT1, KIN, C10orf31, 
MCM10, ANKRD16, CALML5, ECHDC3, AKR1CL2, AKR1C2, CAMK1D, DHTKD1, C10orf111, IL15RA, DCLRE1C, MEIG1, 
ITGA8, LOC439951, FLJ45983, RPP38, PRPF18, ASB13, RSU1, TCEB1P3, FAM107B, CUGBP2, FRMD4A, AKR1C1, 
SEPHS1, ATP5C1, AKR1C4, GDI2, C10orf18, C10orf97, CUBN, SUV39H2, C10orf49, C10orf47, ARMETL1, UCN3, C1QL3, 
ITIH2, UPF2, TUBAL3, LOC100128356, NMT2, LOC389936, CALML3
GATA3
8 5p15.33 0.0204 5 chr5:2179815-3322657 2 genes: C5orf38, IRX2 TERT*
9 10p12.33 0.0204 3 chr10:1-135374737 717 genes -
10 22q11.23 0.0320 9 chr22:20471826-21907111 13 genes: hsa-mir-650, BCR, GNAZ, MAPK1, VPREB1, TOP3B, RAB36, PPM1F, PRAME, RTDR1, GGTLC2, ZNF280A, 
ZNF280B
CRKL*
11 7q35 0.0362 5 chr7:142856201-158821424 103 genes: hsa-mir-595, hsa-mir-153-2, hsa-mir-671, ABP1, CDK5, DPP6, EN2, EZH2, GBX1, MNX1, HTR5A, INSIG1, 
KCNH2, NOS3, PTPRN2, RARRES2, RHEB, SHH, SLC4A2, SMARCD3, VIPR2, XRCC2, ARHGEF5, ZNF212, ZNF282, 
CUL1, ACCN3, PDIA4, UBE3C, FAM115A, DNAJB6, ABCF2, FASTK, ABCB8, PAXIP1, SSPO, CNTNAP2, GIMAP2, OR2F1, 
TPK1, ZNF777, TMEM176B, REPIN1, PRKAG2, NUB1, CSGlcA-T, NCAPG2, WDR60, GIMAP4, GIMAP5, TMEM176A, 
ACTR3B, FAM62B, ZNF398, MLL3, GALNT11, LMBR1, NOM1, LRRC61, ZNF767, TMUB1, KRBA1, C7orf29, CENTG3, 
NOBOX, OR2A14, OR6B1, OR2F2, ZNF786, ASB10, RNF32, GIMAP8, CRYGN, ZNF425, ZNF783, ZNF746, ATP6V0E2, 
CCT8L1, RBM33, GALNTL5, GIMAP7, ZNF467, GIMAP1, C7orf33, TAS2R41, CNPY1, FAM139A, ZNF775, ATG9B, CTAGE6, 
OR2A12, OR2A1, WDR86, OR2A25, OR2A5, OR2A7, OR2A42, LOC402715, LOC441294, OR2A2, FLJ43692, GIMAP6, 
LOC643641
12 1q42.3 0.0410 2 chr1:232738038-232763374 1 gene: IRF2BP2 -
13 4q12 0.0467 4 chr4:55224058-55239617 1 gene: KIT KIT
14 7p11.2 0.0531 3 chr7:54899474-65012069 20 genes: CCT6A, EGFR, GBAS, PHKG1, PSPH, ZNF138, ZNF273, SUMF2, CHCHD2, ZNF117, MRPS17, ZNF107, 
LANCL2, ECOP, ZNF479, VKORC1L1, ZNF92, ZNF680, 14-Sep, ZNF713
EGFR
15 4q13.1 0.0780 9 chr4:63139114-63362224 1 gene: LPHN3 -
16 20q13.2 0.0894 1 chr20:1-62435964 520 genes ZNF217
17 21q22.3 0.156 1 chr21:39772858-46944323 88 genes: ADARB1, AIRE, PTTG1IP, C21orf2, CBS, COL6A1, COL6A2, CRYAA, CSTB, DSCAM, PRMT2, ITGB2, LSS, MX1, 
MX2, NDUFV3, PCNT, PCP4, PDE9A, PFKL, PKNOX1, PWP2, S100B, SH3BGR, SLC19A1, SUMO3, TFF1, TFF2, TFF3, 
TMEM1, TMPRSS2, TRPM2, U2AF1, UBE2G2, C21orf33, PDXK, RRP1, MCM3AP, ABCG1, B3GALT5, WDR4, FTCD, 
HSF2BP, RRP1B, DIP2A, POFUT2, ICOSLG, BACE2, C2CD2, DNMT3L, ZNF295, UBASH3A, SLC37A1, PCBP3, C21orf58, 
C21orf57, C21orf29, FAM3B, RIPK4, AGPAT3, PRDM15, TMPRSS3, COL18A1, LRRC3, C21orf56, C21orf70, RSPH1, 
UMODL1, IGSF5, SNF1LK, PLAC4, KRTAP12-2, KRTAP12-1, KRTAP10-10, C21orf123, KRTAP10-4, KRTAP10-6, 
KRTAP10-7, KRTAP10-9, KRTAP10-1, KRTAP10-11, KRTAP10-2, KRTAP10-5, KRTAP10-8, KRTAP10-3, KRTAP12-3, 
KRTAP12-4, KRTAP10-12
-
1. Rank according to Q-value.  Q-value are false-discovery rate corrected.
2. Cytoband from the middle of the minimal common region.
3. Region represents the wider area that results when the samples defining each border of the minimal common region are left out.
4. Genes of interest related to region:  
       Genes in bold represent significantly amplified genes in cancer from Beroukhim et al. (PMID: 20164920, Supplementary Table 2: GISTIC analysis of 3,131 cancer specimens of 26 tumor types).
       Genes in italics represent genes that are in the region that are mentioned in the text
       Genes with * represent genes adjacent to the region
Supplementary Table 1B: Significant regions of DNA copy number deletion in CTCL
Rank Cytoband Q-value
Number
of
samples
Region Genes in region
Genes of interest 
related to region
1 17p12 1.73E-07 10 chr17:15524281-15794764 4 genes: ADORA2B, TRIM16, ZNF286A, TBC1D26 MAP2K4*, ZNF18*
2 17q25.3 1.73E-07 12 chr17:78226063-78242141 1 gene: RAB40B ZNF750*
3 10p11.22 6.79E-06 4 chr10:30673943-31410094 4 genes: MAP3K8, PAPD1, LYZL2, ZNF438 -
4 7q21.2 1.74E-05 7 chr7:91195291-91198925 1 gene: MTERF -
5 17p13.3 1.74E-05 14 chr17:2109320-2748547 10 genes: MNT, PAFAH1B1, SGSM2, GARNL4, KIAA0664, SMG6, TSR1, SRR, METT10D, LOC284009 TP53*, ATP1B2*
6 16p12.3 1.86E-05 6 chr16:19711348-19743071 1 gene: IQCK -
7 1q31.2 0.000481 5 chr1:191421896-191426345 2 genes: B3GALT2, CDC73 -
8 8p11.21 0.000481 7 chr8:42269520-42277830 1 gene: IKBKB C8orf4*, ZMAT4*
9 10q23.33 0.00288 4 chr10:60671322-97354704 211 genes PTEN
10 10p11.23 0.00346 7 chr10:29478793-30143973 4 genes: hsa-mir-938, hsa-mir-604, SVIL, LYZL1 -
11 9p21.3 0.00376 3 chr9:21790514-22605798 4 genes: CDKN2A, CDKN2B, MTAP, DMRTA1 CDKN2A
12 2q37.1 0.0121 3 chr2:232785309-232823401 1 gene: DIS3L2 TMEM16G, ING5
13 12q15 0.0121 3 chr12:66948191-66954650 1 gene: IL22 -
14 12q21.1 0.0121 3 chr12:69853599-69876390 1 gene: TSPAN8 -
15 4p13 0.0128 4 chr4:43100100-43137404 1 gene: LOC389207 -
16 8p23.2 0.0133 4 chr8:3570501-12646620 57 genes: hsa-mir-598, hsa-mir-124a-1, hsa-mir-597, ANGPT2, BLK, CTSB, DEFA1, DEFA3, DEFA4, DEFA5, DEFA6, DEFB1, 
DEFB4, FDFT1, GATA4, MSRA, TNKS, MFHAS1, SPAG11B, PINX1, AGPAT5, DEFB103A, CSMD1, MTMR9, MCPH1, 
PPP1R3B, SOX7, C8orf13, AMAC1L2, FAM86B1, THEX1, LONRF1, RP1L1, CLDN23, DEFB104A, PRAGMIN, UNQ9391, 
C8orf74, DEFB105A, DEFB106A, DEFB107A, DEFB130, NEIL2, XKR6, DUB3, XKR5, DEFB103B, DEFB107B, DEFB104B, 
DEFB106B, DEFB105B, DEFB136, DEFB137, DEFB134, SPAG11A, LOC728358, LOC728957, 
CSMD1
17 22q11.23 0.0144 6 chr22:22564665-23056324 10 genes: DDT, GGT5, GSTT1, GSTT2, MIF, SPECC1L, CABIN1, SUSD2, GSTT2B, DDTL VPREB1*
18 7p21.1 0.0150 3 chr7:16820392-17640380 2 genes: AHR, AGR3 -
19 9q21.2 0.0184 5 chr9:80289820-92881841 43 genes: hsa-mir-7-1, CKS2, CTSL1, DAPK1, EDG3, GAS1, HNRPK, NTRK2, SYK, TLE1, TLE4, SEMA4D, GADD45G, 
SPIN1, AGTPBP1, CCRK, UBQLN1, GOLM1, SHC3, DIRAS2, KIF27, MAK10, SLC28A3, SECISBP2, ZCCHC6, RMI1, 
GKAP1, ISCA1, C9orf64, NXNL2, RASEF, FRMD3, C9orf47, C9orf79, LOC286238, C9orf164, FLJ46321, C9orf153, CTSL3, 
FLJ45537, FAM75B, C9orf103, CHCHD9
-
20 13q21.1 0.0184 4 chr13:54591155-54593583 1 gene: FLJ40296 RB1*
21 12p13.2 0.0399 7 chr12:10860835-11642691 18 genes: PRB1, PRB3, PRB4, PRH1, PRH2, PRR4, TAS2R13, TAS2R10, TAS2R14, TAS2R43, TAS2R44, TAS2R46, 
TAS2R47, TAS2R48, TAS2R49, TAS2R50, TAS2R42, PRB2
ETV6*
22 6q24.1 0.0596 3 chr6:141733503-163657589 99 genes: ACAT2, ESR1, FUCA2, GRM1, HIVEP2, IGF2R, LPA, MAS1, MAP3K4, NMBR, OPRM1, PARK2, PCMT1, PLAGL1, 
PLG, SLC22A1, SLC22A3, SLC22A2, SOD2, TCP1, DYNLT1, UTRN, EZR, VIP, EPM2A, PEX3, STX11, SYNJ2, LATS1, 
WTAP, AKAP12, PHACTR2, UST, RAB32, KATNA1, RBM16, MAP3K7IP2, SASH1, SYNE1, MTHFD1L, PIP3-E, TIAM2, 
FBXO5, RGS17, MRPL18, CLDN20, NOX3, TFB1M, AIG1, SNX9, VTA1, MTRF1L, RMND1, AGPAT4, TULP4, GPR126, 
PLEKHG1, ARID1B, TMEM181, ZBTB2, ULBP3, C6orf211, ZDHHC14, C6orf103, C6orf97, MYCT1, ULBP2, ULBP1, LPAL2, 
PPP1R14C, SF3B5, RSPH3, FBXO30, FNDC1, LRP11, LTV1, SERAC1, PPIL4, SYTL3, C6orf72, TAGAP, ADAT2, STXBP5, 
PACRG, RAET1E, CNKSR3, RAET1L, PNLDC1, LOC202459, SHPRH, ZC3H12D, NUP43, RAET1G, C6orf98, SUMO4, 
SAMD5, IYD, LOC389435, GTF2H5, 
 
-
23 10q21.1 0.0596 4 chr10:50229783-58152761 27 genes: hsa-mir-605, CHAT, ERCC6, MBL2, MSMB, PRKG1, SLC18A3, NCOA4, PARG, TIMM23, ZWINT, DKK1, CSTF2T, 
A1CF, FAM21B, OGDHL, ASAH2, PCDH15, SGMS1, PGBD3, C10orf53, FAM21A, CTGLF3, DRGX, CTGLF4, ASAH2B, 
CTGLF5
-
24 19p13.3 0.0596 11 chr19:3178103-5466792 54 genes: hsa-mir-7-3, hsa-mir-637, DAPK3, EEF2, MATK, NFIC, MAP2K2, PTPRS, SH3GL1, TBXA2R, APBA3, CHAF1A, 
EBI3, M6PRBP1, HMG20B, SEMA6B, JMJD2B, ZFR2, PIP5K1C, TJP3, ITGB1BP3, UHRF1, ZBTB7A, FZR1, SIRT6, PIAS4, 
FEM1A, STAP2, CCDC94, C19orf10, SHD, C19orf29, BRUNOL5, FSD1, UBXD1, DOHH, CREB3L3, HDGF2, RAX2, MPND, 
ATCAY, DPP9, MRPL54, LRG1, TMIGD2, TNFAIP8L1, C19orf28, GIPC3, TICAM1, ZNRF4, ANKRD24, LSDP5, ARRDC5, 
KIAA1881
GZMM*, THEG*, PPAP2C*, 
C19orf20*
25 10p15.1 0.0610 3 chr10:3931317-3941491 1 gene: KLF6 -
26 3q11.2 0.0676 2 chr3:99583690-99616246 1 gene: OR5K3 -
27 3q13.2 0.0849 2 chr3:113854947-124236792 70 genes: hsa-mir-198, hsa-mir-568, ADPRH, ATP6V1A, CASR, CD80, CD86, CSTA, DRD3, GAP43, GOLGB1, GSK3B, 
GTF2E1, HCLS1, HGD, KPNA1, LSAMP, NDUFB4, SLC15A2, UPK1B, ZNF80, B4GALT4, NR1I2, STXBP5L, IQCB1, COX17, 
POLQ, FSTL1, C3orf17, ZBTB20, C3orf28, GTPBP8, C3orf1, PLA1A, FBXO40, SEMA5B, WDR5B, PARP14, GRAMD1C, 
SIDT1, TMEM39A, WDR52, EAF2, KTELC1, CDGAP, KIAA1407, POPDC2, HSPBAP1, QTRTD1, NAT13, PARP9, DIRC2, 
C3orf15, BOC, LRRC58, CCDC58, CD200R1, DTX3L, CCDC52, IGSF11, C3orf30, PARP15, GPR156, VSTM3, KIAA2018, 
ZDHHC23, RABL3, ILDR1, CD200R2, ARGFX
LSAMP
28 6p21.1 0.0877 4 chr6:41292490-41342376 1 gene: TREML4 -
29 16p13.12 0.0877 2 chr16:14139929-14166178 1 gene: MKL2 -
30 2p11.2 0.125 2 chr2:85892717-85927786 1 gene: ST3GAL5 -
31 13q32.3 0.133 1 chr13:1-114142980 302 genes RB1, LATS2
32 1p36.13 0.149 2 chr1:19552461-19610776 1 gene: CAPZB -
33 4p12 0.153 2 chr4:47936218-47954681 1 gene: TEC -
34 1p36.11 0.155 3 chr1:25408676-28385091 64 genes: CD52, EXTL1, EYA3, FGR, IFI6, SFN, GPR3, HMGN2, STMN1, PAFAH2, PPP1R8, PTAFR, RHCE, RHD, RPA2, 
RPS6KA1, SLC9A1, SLC30A2, ARID1A, NR0B2, FCN3, MAP3K6, C1orf38, WASF2, CNKSR1, NUDC, WDTC1, TMEM50A, 
STX12, SYF2, LDLRAP1, AHDC1, SMPDL3B, ZNF593, ATPBD1B, AIM1L, XKR8, TMEM57, PIGV, FAM54B, C1orf63, 
MAN1C1, SEPN1, GPATCH3, CCDC21, C1orf135, LIN28, GRRP1, DHDDS, SH3BGRL3, C1orf160, ZDHHC18, TRIM63, 
SYTL1, UBXD5, FAM46B, C1orf172, PDIK1L, PAQR7, FAM76A, ZNF683, CATSPER4, LOC388610, CD164L2
SFN
35 8q12.3 0.155 2 chr8:60048458-67666248 23 genes: hsa-mir-124a-2, ASPH, CA8, CRH, MYBL1, PDE7A, RAB2A, TTPA, GGH, CYP7B1, MTFR1, TOX, RRS1, BHLHB5, 
ARMC1, CHD7, TRIM55, DNAJC5B, ADHFE1, RLBP1L1, YTHDF3, C8orf46, NKAIN3
-
36 14q11.2 0.155 6 chr14:19800971-22103068 43 genes: ANG, APEX1, HNRNPC, NP, RNASE1, RNASE2, RNASE3, RNASE4, RNASE6, SALL2, TEP1, TOX4, PARP2, 
FAM12A, SUPT16H, OR10G3, OR10G2, OR4E2, SLC39A2, ZNF219, OSGEP, FLJ10357, METTL3, RPGRIP1, NDRG2, 
CHD8, CCNB1IP1, FAM12B, METT11D1, RNASE7, RAB2B, TMEM55B, TTC5, RNASE11, TPPP2, RNASE8, KLHL33, 
RNASE10, OR6S1, RNASE9, OR5AU1, RNASE13, RNASE12
ZNF219, NDRG2
37 11q22.3 0.163 3 chr11:103469638-116739377 89 genes: hsa-mir-34c, ACAT1, APOA1, APOA4, APOC3, ATM, CASP1, CASP4, CASP5, CRYAB, DDX10, DLAT, DRD2, 
FDX1, GRIA4, GUCY1A2, HSPB2, HTR3A, IL18, NCAM1, NNMT, NPAT, PAFAH1B2, POU2AF1, PPP2R1B, PTS, RDX, 
SDHD, SLN, TAGLN, ZBTB16, CUL5, ZNF259, PCSK7, HTR3B, ZW10, RBM7, CEP164, EXPH5, SNF1LK2, KIAA0999, 
BACE1, CADM1, REXO2, TIMM8B, SIDT2, C11orf71, SLC35F2, RAB39, BTG4, FAM55D, TTC12, C11orf57, ELMOD1, 
TEX12, ARHGAP20, USP28, ICEBERG, AASDHPPT, C11orf1, ALG9, PDGFD, TMPRSS5, BCDO2, KIAA1826, BUD13, 
DIXDC1, ZC3H12C, ALKBH8, LOC91893, C11orf52, COP1, APOA5, PIH1D2, FAM55A, KBTBD3, CWF19L2, KDELC2, LAYN, 
C11orf65, ANKK1, RNF214, C11orf53, LOC399947, FLJ45803, FLJ46266, INCA, LOC643923, LOC644672
ATM, CADM1
38 8q22.1 0.169 4 chr8:95625564-95627290 1 gene: KIAA1429 -
39 5q33.1 0.205 2 chr5:151480736-151502520 1 gene: GLRA1 -
40 4q31.3 0.223 2 chr4:153897161-153915365 1 gene: TIGD4 -
1. Rank according to Q-value.  Q-value are false-discovery rate corrected.
2. Cytoband from the middle of the minimal common region.
3. Region represents the wider area that results when the samples defining each border of the minimal common region are left out.
4. Genes of interest related to region:  
       Genes in bold represent the most significantly deleted genes in cancer from Beroukhim et al. (PMID: 20164920, Supplementary Table 2: GISTIC analysis of 3,131 cancer specimens of 26 tumor types).
       Genes in italics represent genes that are in the region that are mentioned in the text
       Genes with * represent genes adjacent to the region
